Defunct Company
Total Trials
1
As Lead Sponsor
As Collaborator
0
Total Enrollment
19
NCT02040506
A Phase I Study of IGN523 in Subjects With Relapsed or Refractory AML
Phase: Phase 1
Role: Lead Sponsor
Start: Feb 28, 2014
Completion: Jun 30, 2015